

SUPPLEMENTARY MATERIAL

Supplemental Table 1: Summary of humoral responses in Healthy Adults, Older Adults, and Adults with Comorbidities

	Healthy Adults		Older Adults		Adults with Comorbidities	
	CoVLP 3.75 µg +AS03	Placebo	CoVLP 3.75 µg +AS03	Placebo	CoVLP 3.75 µg +AS03	Placebo
NAb Titer						
<u>Day 0</u>						
GMT (95CI)	5.3 (5.1, 5.6)	5.0 (NE, NE)	5.2 (5.0, 5.5)	5.5 (4.6, 6.6)	8.9 (6.8, 11.6)	13.0 (6.4, 26.2)
<u>Day 21</u>						
GMT (95CI)	44.3 (35.8, 54.8)	5.2 (4.8, 5.6)	29.7 (23.7, 37.1)	5.5 (4.6, 6.5)	49.1 (31.8, 75.7)	20.0 (8.2, 49.0)
<u>Day 42</u>						
GMT (95CI)	2034 (1754, 2358)	5.7 (4.7, 6.8)	1918 (1571, 2342)	5.6 (4.5, 6.9)	1962 (1442, 2667)	36.2 (12.5, 104.7)
Seroconversion Rate						
<u>Day 21</u>						
SCR, % (95CI)	51.3 (44.7, 57.8)	0 (0.0, 8.2)	38.4 (31.9, 45.1)	0 (0.0, 7.9)	44.2 (35.1, 53.5)	7.7 (0.9, 25.1)
<u>Day 42</u>						
SCR, % (95CI)	99.2 (97.0, 99.9)	2.4 (0.1, 12.6)	97.7 (94.7, 99.2)	0 (0.0, 9.0)	95.8 (90.4, 98.6)	17.4 (5.0, 38.8)

NAb: neutralizing antibody, GMT: geometric mean titer, 95CI: 95% confidence interval, SCR: seroconversion rate, NE: not estimable